ClinicalTrials.gg
CompletedNCT02059148Updated Jan 7, 2019Results posted

A Study of LY2835219 in Healthy Participants

A Phase 1 interventional study of LY2835219 in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-07.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Participants in this study will receive 3 single oral doses of LY2835219 at least 14 days apart. One dose will be given with a standard meal, one dose with a high-fat meal and one dose without food. The study will evaluate the effects of the standard and high-fat meals on how much drug gets into the bloodstream. Side effects will be documented. This study is approximately 43 days, not including screening. Screening is required within 28 days prior to the start of the study.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy sterile males or surgically sterile or females
  • Have a (BMI) of 18 to 32 kilogram per meter square (kg/m\^2), inclusive, at screening
  • Are able to eat a high-fat, high-calorie meal

Exclusion criteria

Exclusion Criteria:

  • Participated in a clinical trial involving product within 30 days
  • Abnormal blood pressure
  • Have an abnormality in the 12-lead (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Have donated blood of more than 500 milliliter (mL) within the last month
  • Show evidence of , or
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    LY2835219 Standard

    Single oral dose of LY2835219 given with a standard meal in one of three study periods.

    Drug: LY2835219

  • Experimental
    LY2835219 Fasted

    Single oral dose of LY2835219 given with no food in one of three periods.

    Drug: LY2835219

  • Experimental
    LY2835219 High-Fat

    Single oral dose of LY2835219 given with a high fat meal in one of three periods.

    Drug: LY2835219

Interventions

  • Administered orally.

    Also known as: abemaciclib

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Maximum Concentration (Cmax) of LY2835219 Fasted vs. High-Fat Arms

    Time frame: Predose, 0.5,1,2,3,4,6,8,10,12,24,48,72,96,120,144,168,192 hours post-LY2835219 dose in each period

  2. Pharmacokinetics: Area Under the Concentration Curve (0-t Last) [AUC(0-t Last)] of LY2835219 Fasted vs. High-Fat Arms

    Time frame: Predose, 0.5,1,2,3,4,6,8,10,12,24,48,72,96,120,144,168,192 hours post-LY2835219 dose in each period

  3. Pharmacokinetics: Time of Maximum Observed Concentration (Tmax) of LY2835219 Fasted vs. High-Fat Arms

    Time frame: Predose, 0.5,1,2,3,4,6,8,10,12,24,48,72,96,120,144,168,192 hours post-LY2835219 dose in each period

Secondary outcomes

  1. Pharmacokinetics: Cmax of LY2835219 in Standard Meal Arm

    Time frame: Predose, 0.5,1,2,3,4,6,8,10,12,24,48,72,96,120,144,168,192 hours post-LY2835219 dose in each period

  2. Pharmacokinetics: AUC(0-tlast) of LY2835219 in Standard Meal Arm

    Time frame: Predose, 0.5,1,2,3,4,6,8,10,12,24,48,72,96,120,144,168,192 hours post-LY2835219 dose in each period

  3. Pharmacokinetics: Tmax of LY2835219 in Standard Meal Arm

    Time frame: Predose, 0.5,1,2,3,4,6,8,10,12,24,48,72,96,120,144,168,192 hours post-LY2835219 dose in each period

  4. Pharmacokinetics: Area Under the Concentration Curve (AUC 0-t Last) of LSN3106726 (M20)

    Area under the concentration versus time curve from time zero to time t, where t is the last time point with a measurable concentration of LSN3106726 (M20), an active metabolite of LY2835219.

    Time frame: Predose, 0.5,1,2,3,4,6,8,10,12,24,48,72,96,120,144,168,192 hours post-LY2835219 dose in each period

07

Results

Posted Aug 16, 2018

Participant flow

Treatment 1
Participant flow — Treatment 1
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6
Started444444
Completed444443
Not completed000001
Withdrew: Protocol violation000001
Treatment 2
Participant flow — Treatment 2
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6
Started444443
Completed444443
Not completed000000
Treatment 3
Participant flow — Treatment 3
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6
Started444443
Completed444443
Not completed000000

Outcome measures

PrimaryPharmacokinetics: Maximum Concentration (Cmax) of LY2835219 Fasted vs. High-Fat Arms
Time frame:
Predose, 0.5,1,2,3,4,6,8,10,12,24,48,72,96,120,144,168,192 hours post-LY2835219 dose in each period
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
Pharmacokinetics: Maximum Concentration (Cmax) of LY2835219 Fasted vs. High-Fat Arms
nanogram/milliliter (ng/mL)LY2835219 FastedLY2835219 High-Fat
Pharmacokinetics: Maximum Concentration (Cmax) of LY2835219 Fasted vs. High-Fat Arms111 ± 61137 ± 52
Statistical analysis
  • LY2835219 Fasted vs LY2835219 High-Fat · Ratio of geometric lsmeans: 1.24 · 90% CI 1.11 to 1.38
PrimaryPharmacokinetics: Area Under the Concentration Curve (0-t Last) [AUC(0-t Last)] of LY2835219 Fasted vs. High-Fat Arms
Time frame:
Predose, 0.5,1,2,3,4,6,8,10,12,24,48,72,96,120,144,168,192 hours post-LY2835219 dose in each period
Reported as:
Geometric mean · nanogram*hour/mL (ng*h/mL)
Pharmacokinetics: Area Under the Concentration Curve (0-t Last) [AUC(0-t Last)] of LY2835219 Fasted vs. High-Fat Arms
nanogram*hour/mL (ng*h/mL)LY2835219 FastedLY2835219 High-Fat
Pharmacokinetics: Area Under the Concentration Curve (0-t Last) [AUC(0-t Last)] of LY2835219 Fasted vs. High-Fat Arms4160 ± 654790 ± 57
Statistical analysis
  • LY2835219 Fasted vs LY2835219 High-Fat · Ratio of geometric lsmeans: 1.14 · 90% CI 1.05 to 1.23
PrimaryPharmacokinetics: Time of Maximum Observed Concentration (Tmax) of LY2835219 Fasted vs. High-Fat Arms
Time frame:
Predose, 0.5,1,2,3,4,6,8,10,12,24,48,72,96,120,144,168,192 hours post-LY2835219 dose in each period
Reported as:
Median · hour (h)
Pharmacokinetics: Time of Maximum Observed Concentration (Tmax) of LY2835219 Fasted vs. High-Fat Arms
hour (h)LY2835219 FastedLY2835219 High-Fat
Pharmacokinetics: Time of Maximum Observed Concentration (Tmax) of LY2835219 Fasted vs. High-Fat Arms8.00 (6.00 to 12.00)10.00 (6.00 to 24.00)
Statistical analysis
  • LY2835219 Fasted vs LY2835219 High-Fat · Wilcoxon (Mann-Whitney) · p = 0.0006 · Median difference (final values): 1.95 · 90% CI 1.00 to 2.00
SecondaryPharmacokinetics: Cmax of LY2835219 in Standard Meal Arm
Time frame:
Predose, 0.5,1,2,3,4,6,8,10,12,24,48,72,96,120,144,168,192 hours post-LY2835219 dose in each period
Reported as:
Geometric mean · ng/mL
Pharmacokinetics: Cmax of LY2835219 in Standard Meal Arm
ng/mLLY2835219 Standard
Pharmacokinetics: Cmax of LY2835219 in Standard Meal Arm141 ± 55
SecondaryPharmacokinetics: AUC(0-tlast) of LY2835219 in Standard Meal Arm
Time frame:
Predose, 0.5,1,2,3,4,6,8,10,12,24,48,72,96,120,144,168,192 hours post-LY2835219 dose in each period
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetics: AUC(0-tlast) of LY2835219 in Standard Meal Arm
ng*h/mLLY2835219 Standard
Pharmacokinetics: AUC(0-tlast) of LY2835219 in Standard Meal Arm4610 ± 65
SecondaryPharmacokinetics: Tmax of LY2835219 in Standard Meal Arm
Time frame:
Predose, 0.5,1,2,3,4,6,8,10,12,24,48,72,96,120,144,168,192 hours post-LY2835219 dose in each period
Reported as:
Median · hour (h)
Pharmacokinetics: Tmax of LY2835219 in Standard Meal Arm
hour (h)LY2835219 Standard
Pharmacokinetics: Tmax of LY2835219 in Standard Meal Arm8.00 (6.00 to 10.00)
SecondaryPharmacokinetics: Area Under the Concentration Curve (AUC 0-t Last) of LSN3106726 (M20)

Area under the concentration versus time curve from time zero to time t, where t is the last time point with a measurable concentration of LSN3106726 (M20), an active metabolite of LY2835219.

Time frame:
Predose, 0.5,1,2,3,4,6,8,10,12,24,48,72,96,120,144,168,192 hours post-LY2835219 dose in each period
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetics: Area Under the Concentration Curve (AUC 0-t Last) of LSN3106726 (M20)
ng*h/mLLY2835219 StandardLY2835219 FastedLY2835219 High-Fat
Pharmacokinetics: Area Under the Concentration Curve (AUC 0-t Last) of LSN3106726 (M20)3590 ± 353320 ± 403510 ± 35

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY2835219 Standard—0/23 (0%)4/23 (17.4%)
LY2835219 Fasted—0/23 (0%)6/23 (26.1%)
LY2835219 High-Fat—0/24 (0%)4/24 (16.7%)
Most frequent other events
Most frequent other events
EventLY2835219 StandardLY2835219 FastedLY2835219 High-Fat
NauseaGastrointestinal disorders3/233/230/24
DiarrhoeaGastrointestinal disorders2/230/233/24
Viral upper respiratory tract infectionInfections and infestations0/232/231/24
HeadacheNervous system disorders2/232/230/24

Baseline characteristics

Single Oral Dose of 200 mg LY2835219 on 3 Occasions: Standard Meal, Fasted State, High-Fat Meal.

Age, Continuous
Age, Continuous(Years)All Study Participants
Mean53.9 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female21
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Study Participants
Hispanic or Latino5
Not Hispanic or Latino19
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Study Participants
American Indian or Alaska Native2
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American13
White9
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)All Study Participants
United States24
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75247, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2018, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2014
First posted
Feb 11, 2014
Start
Feb 2014
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Results first posted
Aug 16, 2018
Last update
Jan 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02059148
Responsible party
Sponsor
First posted
Feb 11, 2014
Start date
Feb 2014
Primary completion
Aug 2014
Completion
Aug 2014
Results posted
Aug 16, 2018
Last update
Jan 7, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion